<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230827180640&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230827180640&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sun, 27 Aug 2023 22:06:41 +0000</lastbuilddate>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 27:ehad554. doi: 10.1093/eurheartj/ehad554. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634129/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37634129</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad554>10.1093/eurheartj/ehad554</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634129</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Cristina Procopio</dc:creator>
<dc:creator>Francisco Alpedurada</dc:creator>
<dc:creator>Chiara Bucciarelli-Ducci</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Biventricular Arrhythmogenic Cardiomyopathy: 12-Year Natural History</dc:title>
<dc:identifier>pmid:37634129</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad554</dc:identifier>
</item>
<item>
<title>Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>Background: Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. Methods: In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 27. doi: 10.1161/CIRCULATIONAHA.123.066429. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared to angiography-guided PCI. However, comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown. <b>Methods:</b> In this prospective, multicenter, open-label, pragmatic trial, we randomly assigned 2008 patients with significant coronary-artery lesions undergoing PCI in a 1:1 ratio to undergo either an OCT-guided or IVUS-guided PCI. The primary end point was a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year, which was powered for noninferiority of the OCT group as compared with the IVUS group. Safety outcomes were also assessed. <b>Results:</b> At 1 year, primary end-point events occurred in 25 of 1005 patients (Kaplan-Meier estimate, 2.5%) in the OCT group and in 31 of 1003 patients (Kaplan-Meier estimate, 3.1%) in the IVUS group (absolute difference, -0.6 percentage points; upper boundary of one-sided 97.5% confidence interval, 0.97 percentage points; P&lt;0.001 for noninferiority). The incidence of contrast-induced nephropathy was similar (14 patients [1.4%] in the OCT group vs. 15 patients [1.5%] in the IVUS group, P=0.85). The incidence of major procedural complications was lower in the OCT group than in the IVUS group (22 [2.2%] vs. 37 [3.7%], P=0.047), although imaging procedure-related complications were not observed. <b>Conclusions:</b> In patients with significant coronary-artery lesions, OCT-guided PCI was noninferior to IVUS-guided PCI with respect to the incidence of a composite of death from cardiac causes, target-vessel-related myocardial infarction, or ischemia-driven target-vessel revascularization at 1 year. The selected study population and lower than expected event rates should be considered in interpreting the trial.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37634092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37634092</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066429>10.1161/CIRCULATIONAHA.123.066429</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37634092</guid>
<pubDate>Sun, 27 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Sung-Cheol Yun</dc:creator>
<dc:creator>Seung Ho Hur</dc:creator>
<dc:creator>Yun-Kyeong Cho</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Subin Lim</dc:creator>
<dc:creator>Sang-Wook Kim</dc:creator>
<dc:creator>Hoyoun Won</dc:creator>
<dc:creator>Jun-Hyok Oh</dc:creator>
<dc:creator>Jeong Cheon Choe</dc:creator>
<dc:creator>Young Joon Hong</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Young Won Yoon</dc:creator>
<dc:creator>Soo-Joong Kim</dc:creator>
<dc:creator>Jang Ho Bae</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>OCTIVUS Investigators</dc:creator>
<dc:date>2023-08-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optical Coherence Tomography-Guided or Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37634092</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066429</dc:identifier>
</item>
<item>
<title>Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO^(mod)) with a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 22:S0092-8674(23)00852-8. doi: 10.1016/j.cell.2023.07.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Thrombopoietin (THPO or TPO) is an essential cytokine for hematopoietic stem cell (HSC) maintenance and megakaryocyte differentiation. Here, we report the 3.4 Å resolution cryoelectron microscopy structure of the extracellular TPO-TPO receptor (TpoR or MPL) signaling complex, revealing the basis for homodimeric MPL activation and providing a structural rationalization for genetic loss-of-function thrombocytopenia mutations. The structure guided the engineering of TPO variants (TPO<sup>mod</sup>) with a spectrum of signaling activities, from neutral antagonists to partial- and super-agonists. Partial agonist TPO<sup>mod</sup> decoupled JAK/STAT from ERK/AKT/CREB activation, driving a bias for megakaryopoiesis and platelet production without causing significant HSC expansion in mice and showing superior maintenance of human HSCs in vitro. These data demonstrate the functional uncoupling of the two primary roles of TPO, highlighting the potential utility of TPO<sup>mod</sup> in hematology research and clinical HSC transplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37633268</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.037>10.1016/j.cell.2023.07.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37633268</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Naotaka Tsutsumi</dc:creator>
<dc:creator>Zahra Masoumi</dc:creator>
<dc:creator>Sophie C James</dc:creator>
<dc:creator>Julie A Tucker</dc:creator>
<dc:creator>Hauke Winkelmann</dc:creator>
<dc:creator>William Grey</dc:creator>
<dc:creator>Lora K Picton</dc:creator>
<dc:creator>Lucie Moss</dc:creator>
<dc:creator>Steven C Wilson</dc:creator>
<dc:creator>Nathanael A Caveney</dc:creator>
<dc:creator>Kevin M Jude</dc:creator>
<dc:creator>Cornelius Gati</dc:creator>
<dc:creator>Jacob Piehler</dc:creator>
<dc:creator>Ian S Hitchcock</dc:creator>
<dc:creator>K Christopher Garcia</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis</dc:title>
<dc:identifier>pmid:37633268</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.037</dc:identifier>
</item>
<item>
<title>PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson's disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 21:S0092-8674(23)00862-0. doi: 10.1016/j.cell.2023.08.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Selective clearance of organelles, including endoplasmic reticulum (ER) and mitochondria, by autophagy plays an important role in cell health. Here, we describe a developmentally programmed selective ER clearance by autophagy. We show that Parkinson's disease-associated PINK1, as well as Atl, Rtnl1, and Trp1 receptors, regulate ER clearance by autophagy. The E3 ubiquitin ligase Parkin functions downstream of PINK1 and is required for mitochondrial clearance while having the opposite function in ER clearance. By contrast, Keap1 and the E3 ubiquitin ligase Cullin3 function downstream of PINK1 to regulate ER clearance by influencing Rtnl1 and Atl. PINK1 regulates a change in Keap1 localization and Keap1-dependent ubiquitylation of the ER-phagy receptor Rtnl1 to facilitate ER clearance. Thus, PINK1 regulates the selective clearance of ER and mitochondria by influencing the balance of Keap1- and Parkin-dependent ubiquitylation of substrates that determine which organelle is removed by autophagy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37633267</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.008>10.1016/j.cell.2023.08.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37633267</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ruoxi Wang</dc:creator>
<dc:creator>Tina M Fortier</dc:creator>
<dc:creator>Fei Chai</dc:creator>
<dc:creator>Guangyan Miao</dc:creator>
<dc:creator>James L Shen</dc:creator>
<dc:creator>Lucas J Restrepo</dc:creator>
<dc:creator>Jeromy J DiGiacomo</dc:creator>
<dc:creator>Panagiotis D Velentzas</dc:creator>
<dc:creator>Eric H Baehrecke</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development</dc:title>
<dc:identifier>pmid:37633267</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.008</dc:identifier>
</item>
<item>
<title>Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad568. doi: 10.1093/eurheartj/ehad568. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad568>10.1093/eurheartj/ehad568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632844</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Janine Pöss</dc:creator>
<dc:creator>Petra Büttner</dc:creator>
<dc:creator>Holger Thiele</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Circulating dipeptidyl peptidase 3 - New hope for a specific treatment to improve prognosis in cardiogenic shock?</dc:title>
<dc:identifier>pmid:37632844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad568</dc:identifier>
</item>
<item>
<title>Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad506. doi: 10.1093/eurheartj/ehad506. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632758</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad506>10.1093/eurheartj/ehad506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632758</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Colin Baigent</dc:creator>
<dc:creator>Rafael Sádaba</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence</dc:title>
<dc:identifier>pmid:37632758</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad506</dc:identifier>
</item>
<item>
<title>2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad476. doi: 10.1093/eurheartj/ehad476. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In October 2021, the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) jointly agreed to establish a Task Force (TF) to review recommendations of the 2018 ESC/EACTS Guidelines on myocardial revascularization as they apply to patients with left main (LM) disease with low-to-intermediate SYNTAX score (0-32). This followed the withdrawal of support by the EACTS in 2019 for the recommendations about the management of LM disease of the previous guideline. The TF was asked to review all new relevant data since the 2018 guidelines including updated aggregated data from the four randomized trials comparing percutaneous coronary intervention (PCI) with drug-eluting stents vs. coronary artery bypass grafting (CABG) in patients with LM disease. This document represents a summary of the work of the TF; suggested updated recommendations for the choice of revascularization modality in patients undergoing myocardial revascularization for LM disease are included. In stable patients with an indication for revascularization for LM disease, with coronary anatomy suitable for both procedures and a low predicted surgical mortality, the TF concludes that both treatment options are clinically reasonable based on patient preference, available expertise, and local operator volumes. The suggested recommendations for revascularization with CABG are Class I, Level of Evidence A. The recommendations for PCI are Class IIa, Level of Evidence A. The TF recognized several important gaps in knowledge related to revascularization in patients with LM disease and recognizes that aggregated data from the four randomized trials were still only large enough to exclude large differences in mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632756</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad476>10.1093/eurheartj/ehad476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632756</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Robert A Byrne</dc:creator>
<dc:creator>Stephen Fremes</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Martin Czerny</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Jonathan R Emberson</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Milan Milojevic</dc:creator>
<dc:creator>Miguel Sousa Uva</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy suitable for PCI or CABG</dc:title>
<dc:identifier>pmid:37632756</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad476</dc:identifier>
</item>
<item>
<title>Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad545. doi: 10.1093/eurheartj/ehad545. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Plasma cDPP3 levels were assessed at baseline and 12-24 hours after presentation in patients with ACS prospectively enrolled into the multicentre SPUM-ACS study (n = 4787).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score (per log-2 increase, hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.05-1.82, P = 0.021). High cDPP3 was as an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P &lt; 0.001) and at 1 year (HR 1.61, 95% CI 1.28-2.02, P &lt; 0.001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 hours were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P &lt; 0.001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P &lt; 0.001). Results were consistent across various patient subgroups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632743</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad545>10.1093/eurheartj/ehad545</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632743</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Florian A Wenzl</dc:creator>
<dc:creator>Francesco Bruno</dc:creator>
<dc:creator>Simon Kraler</dc:creator>
<dc:creator>Roland Klingenberg</dc:creator>
<dc:creator>Alexander Akhmedov</dc:creator>
<dc:creator>Stefano Ministrini</dc:creator>
<dc:creator>Karine Santos</dc:creator>
<dc:creator>Konstantin Godly</dc:creator>
<dc:creator>Julia Godly</dc:creator>
<dc:creator>David Niederseer</dc:creator>
<dc:creator>Robert Manka</dc:creator>
<dc:creator>Andreas Bergmann</dc:creator>
<dc:creator>Giovanni G Camici</dc:creator>
<dc:creator>Arnold von Eckardstein</dc:creator>
<dc:creator>Barbara Stähli</dc:creator>
<dc:creator>Olivier Muller</dc:creator>
<dc:creator>Marco Roffi</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes</dc:title>
<dc:identifier>pmid:37632743</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad545</dc:identifier>
</item>
<item>
<title>Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093/eurheartj/ehad584. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guideline-directed medical therapy (GDMT) is recommended prior to mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with left ventricular ejection fraction (LVEF) &lt; 50% who underwent MTEER for FMR from July 23, 2019 to March 31, 2022 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were identified. Pre-procedure GDMT utilization was assessed. Cox proportional hazards models were constructed to evaluate associations between pre-MTEER therapy (no/single, double, or triple therapy) and risk of one-year mortality or HF hospitalization (HFH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4,199 patients across 449 sites, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitor were used in 85.1%, 44.4%, 28.6%, and 19.9% prior to MTEER, respectively. Triple therapy was prescribed for 19.2%, double therapy for 38.2%, single therapy for 36.0%, and 6.5% were on no GDMT. Significant center-level variation in the proportion of patients on pre-intervention triple therapy was observed (0-61%; adjusted median odds ratio 1.48 [95% confidence interval (CI) 1.25-3.88]; P &lt; 0.001). In patients eligible for one-year follow-up (n = 2,014; 341 sites), the composite rate of one-year mortality or HFH was lowest in patients prescribed triple therapy (23.1%) compared with double (24.8%), single (35.7%), and no (41.1%) therapy (P &lt; 0.01 comparing across groups). Associations persisted after accounting for relevant clinical characteristics, with lower risk in patients prescribed triple therapy (adjusted hazard ratio [aHR] 0.73, 95% CI 0.55-0.97) and double therapy (aHR 0.69, 95% CI 0.56-0.86) prior to MTEER compared with no/single therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Under one-fifth of patients with LVEF &lt;50% who underwent MTEER for FMR in this US nationwide registry were prescribed comprehensive GDMT, with substantial variation across sites. Compared with no/single therapy, triple and double therapy prior to MTEER were independently associated with reduced risk of mortality or HFH one year after intervention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632738</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad584>10.1093/eurheartj/ehad584</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632738</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Anubodh S Varshney</dc:creator>
<dc:creator>Miloni Shah</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Andrzej Kosinski</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Sameer Hirji</dc:creator>
<dc:creator>Ersilia M DeFilippis</dc:creator>
<dc:creator>Pinak B Shah</dc:creator>
<dc:creator>Mona Fiuzat</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Tsuyoshi Kaneko</dc:creator>
<dc:creator>Michael M Givertz</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry</dc:title>
<dc:identifier>pmid:37632738</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad584</dc:identifier>
</item>
<item>
<title>Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>Background: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown. We compared the prognostic and predictive value of these types of lipoprotein(a) tests for major adverse cardiovascular events (mace). <b>Methods:</b> The odyssey outcomes trial compared the pcsk9i alirocumab with placebo in patients with recent acute coronary syndrome (acs). We compared risk of mace in the placebo group and mace risk reduction with alirocumab according to baseline lipoprotein(a) concentration measured by siemens n-latex nephelometric immunoassay (ia-mass, mg/dl), roche tina-quant® turbidimetric immunoassay (ia-molar, nmol/l), and a non-commercial mass spectrometry-based test (ms, nmol/l). Lipoprotein(a) values were transformed into percentiles for comparative modeling. Natural cubic splines estimated continuous relationships between baseline lipoprotein(a) and outcomes in each treatment group. Event rates were also determined across baseline lipoprotein(a) quartiles defined by each assay. <b>Results:</b> Among 11,970 trial participants with results from all 3 tests, baseline median (q1, q3) lipoprotein(a) concentrations were 21.8 (6.9, 60.0) mg/dl, 45.0 (13.2, 153.8) nmol/l, and 42.2 (14.3, 143.1) nmol/l for ia-mass, ia-molar, and ms, respectively. The strongest correlation was between ia-molar and ms (r=0.990), with nominally weaker correlations between ia-mass and ms (r=0.967) and ia-mass and ia-molar (r=0.972). Relationships of lipoprotein(a) with mace risk in the placebo group were nearly identical with each test with estimated cumulative incidences differing by ≤0.4% across lipoprotein(a) percentiles, and all were incrementally prognostic after accounting for ldl-c (all spline p≤0.0003). Predicted alirocumab treatment effects were also nearly identical for each of the three tests, with estimated treatment hazard ratios (hrs) differing by ≤0.07 between tests across percentiles and nominally less relative risk reduction by alirocumab at lower percentiles for all three tests. Absolute risk reduction with alirocumab increased with increasing lipoprotein(a) measured by each test, with significant linear trends across quartiles. <b>Conclusions:</b> In patients with recent acs, three lipoprotein(a) tests were similarly prognostic for mace in the placebo group and predictive of mace reductions with alirocumab at the cohort level.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632469</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066398>10.1161/CIRCULATIONAHA.123.066398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632469</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Esther Reijnders</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Vera A Bittner</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Sergio Fazio</dc:creator>
<dc:creator>Genevieve Garon</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>L Renee Ruhaak</dc:creator>
<dc:creator>Markus Schwertfeger</dc:creator>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Harvey D White</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>Christa Cobbaert</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>ODYSSEY OUTCOMES Investigators</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests</dc:title>
<dc:identifier>pmid:37632469</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066398</dc:identifier>
</item>
<item>
<title>Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>Background: Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. Methods: In this prespecified analysis of the DELIVER...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all patients experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification of diuretics is common in response to symptoms of worsening HF, yet its prognostic and clinical relevance, specifically in patient with HF with mildly reduced or preserved ejection fraction is uncertain. <b>Methods:</b> In this <i>prespecified</i> analysis of the DELIVER trial, we assessed the association between various non-fatal worsening HF events (those requiring hospitalization, urgent outpatient visits requiring intravenous HF therapies, and outpatient oral diuretic intensification) and rates of subsequent mortality. We further examined the treatment effect of dapagliflozin on an expanded composite endpoint of CV death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification. <b>Results:</b> In DELIVER, 4,532 (72%) patients experienced no worsening HF event, while 789 (13%) had outpatient oral diuretic intensification, 86 (1%) required an urgent HF visit, 585 (9%) had a HF hospitalization, and 271 (4%) died of CV causes as a first presentation. Patients with a first presentation manifesting as outpatient oral diuretic intensification experienced rates of subsequent mortality that were higher (10[8-12] per 100py) than those without a worsening HF event (4[3-4] per 100py) but similar to rates of subsequent death following urgent HF visit (10[6-18] per 100py). Patients with a HF hospitalization as a first presentation of worsening HF had the highest rates of subsequent death (35[31-40] per 100py). The addition of outpatient diuretic intensification to the adjudicated DELIVER primary endpoint (CV death, HF hospitalization, or urgent HF visit) increased the overall number of patients experiencing an event from 1,122 to 1,731 (a 54% increase). Dapagliflozin reduced the need for outpatient diuretic intensification alone (HR 0.72; 95% CI: 0.64-0.82) and when analyzed as a part of an expanded composite endpoint of worsening HF or CV death (HR 0.76; 95% CI: 0.69-0.84). <b>Conclusions:</b> In patients with HF with mildly reduced or preserved ejection fraction, worsening HF requiring oral diuretic intensification in ambulatory care was frequent, adversely prognostic, and significantly reduced by dapagliflozin.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632455</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066506>10.1161/CIRCULATIONAHA.123.066506</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632455</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Rudolf A De Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna-Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial</dc:title>
<dc:identifier>pmid:37632455</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066506</dc:identifier>
</item>
<item>
<title>Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093/eurheartj/ehad591. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: De novo implanted cardiac resynchronisation therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this multicentre, randomised, controlled trial, 360 symptomatic (New York Heart Association class II-IVa) HFrEF patients with a pacemaker or implantable cardioverter defibrillator (ICD), high RVP burden ≥20%, and a wide, paced QRS complex duration ≥150 ms were randomly assigned to receive CRT-D upgrade (n = 215) or ICD (n = 145) in a 3:2 ratio. The primary outcome was the composite of all-cause mortality, heart failure hospitalisation or &lt;15% reduction of left ventricular end-systolic volume assessed at 12 months. Secondary outcomes included all-cause mortality or heart failure hospitalisation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 12.4 months, the primary outcome occurred in 58/179 (32.4%) in the CRT-D arm vs. 101/128 (78.9%) in the ICD arm [odds ratio 0.11; 95% confidence interval (CI) 0.06-0.19; p &lt; 0.001]. All-cause mortality or heart failure hospitalization occurred in 22/215 (10%) in the CRT-D arm vs. 46/145 (32%) in the ICD arm (hazard ratio 0.27; 95% CI 0.16-0.47; p &lt; 0.001). The incidence of procedure- or device-related complications was similar between the two arms [CRT-D group 25/211 (12.3%) vs. ICD group 11/142 (7.8%)].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In pacemaker or ICD patients with significant RVP burden and reduced ejection fraction, upgrade to CRT-D compared to ICD therapy reduced the combined risk of all-cause mortality, heart failure hospitalisation or absence of reverse remodelling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632437</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad591>10.1093/eurheartj/ehad591</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632437</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Robert Hatala</dc:creator>
<dc:creator>Jerzy K Wranicz</dc:creator>
<dc:creator>Gábor Duray</dc:creator>
<dc:creator>Csaba Földesi</dc:creator>
<dc:creator>Zoltán Som</dc:creator>
<dc:creator>Marianna Németh</dc:creator>
<dc:creator>Kinga Goscinska-Bis</dc:creator>
<dc:creator>László Gellér</dc:creator>
<dc:creator>Endre Zima</dc:creator>
<dc:creator>István Osztheimer</dc:creator>
<dc:creator>Levente Molnár</dc:creator>
<dc:creator>Júlia Karády</dc:creator>
<dc:creator>Gerhard Hindricks</dc:creator>
<dc:creator>Ilan Goldenberg</dc:creator>
<dc:creator>Helmut Klein</dc:creator>
<dc:creator>Mátyás Szigeti</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Valentina Kutyifa</dc:creator>
<dc:creator>Attila Kovács</dc:creator>
<dc:creator>Annamária Kosztin</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial</dc:title>
<dc:identifier>pmid:37632437</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad591</dc:identifier>
</item>
<item>
<title>The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093/eurheartj/ehad588. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad588>10.1093/eurheartj/ehad588</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632436</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Cecilia Linde</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction</dc:title>
<dc:identifier>pmid:37632436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad588</dc:identifier>
</item>
<item>
<title>Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093/eurheartj/ehad586. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency (ID) and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patient-level data from randomized, placebo-controlled FCM trials including adults with HF and ID with ≥52 weeks follow-up were analysed. The co-primary efficacy endpoints were (1) composite of total/recurrent cardiovascular hospitalizations and cardiovascular death, and (2) composite of total HF hospitalizations and cardiovascular death, through 52 weeks. Key secondary endpoints included individual composite endpoint components. Event rates were analysed using a negative binomial model. Treatment-emergent adverse events were also examined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Three FCM trials with a total of 4501 patients were included. FCM was associated with a significantly reduced risk of co-primary endpoint 1 (rate ratio [RR] 0.86; 95% confidence interval [CI] 0.75-0.98; P=0.029; Cochran Q: 0.008), with a trend towards a reduction of co-primary endpoint 2 (RR 0.87; 95% CI 0.75-1.01; P=0.076; Cochran Q: 0.024). Treatment effects appeared to result from reduced hospitalization rates, not improved survival. Treatment appeared to have a good safety profile and was well-tolerated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632415</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad586>10.1093/eurheartj/ehad586</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632415</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Bernard Roubert</dc:creator>
<dc:creator>Nicole Blackman</dc:creator>
<dc:creator>Tim Friede</dc:creator>
<dc:creator>Ewa A Jankowska</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis</dc:title>
<dc:identifier>pmid:37632415</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad586</dc:identifier>
</item>
<item>
<title>Plasma cholesterol levels in infancy: a neglected resource</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad558. doi: 10.1093/eurheartj/ehad558. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632413</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad558>10.1093/eurheartj/ehad558</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632413</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Kirsten B Holven</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plasma cholesterol levels in infancy: a neglected resource</dc:title>
<dc:identifier>pmid:37632413</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad558</dc:identifier>
</item>
<item>
<title>Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Lipid parameters changed during the first 14-16 months of life, and sex, gestational age, birth weight, breastfeeding, and high parental concentrations influenced concentrations. Children with high concentrations of atherogenic lipid traits at birth had higher concentrations at 2 and 14-16 months. These findings increase our knowledge of how lipid traits develop over the first 14-16 months of life and may help in deciding the optimal child age for universal familial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad547. doi: 10.1093/eurheartj/ehad547. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The aims of this study were to investigate lipid parameters during the first 14-16 months of life, to identify influential factors, and to test whether high concentrations at birth predict high concentrations at 2- and 14-16 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Copenhagen Baby Heart Study, including 13,354 umbilical cord blood samples and parallel venous blood samples from children and parents at birth (n = 444), 2 months (n = 364), and 14-16 months (n = 168), was used.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Concentrations of lipids, lipoproteins, and apolipoproteins in umbilical cord blood samples correlated highly with venous blood samples from newborns. Concentrations of low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (HDL) cholesterol, apolipoprotein B, and lipoprotein(a) increased stepwise from birth to 2 months to 14-16 months. Linear mixed models showed that concentrations of LDL cholesterol, non-HDL cholesterol, and lipoprotein(a) above the 80th percentile at birth were associated with significantly higher concentrations at 2 and 14-16 months. Finally, lipid concentrations differed according to sex, gestational age, birth weight, breastfeeding, and parental lipid concentrations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Lipid parameters changed during the first 14-16 months of life, and sex, gestational age, birth weight, breastfeeding, and high parental concentrations influenced concentrations. Children with high concentrations of atherogenic lipid traits at birth had higher concentrations at 2 and 14-16 months. These findings increase our knowledge of how lipid traits develop over the first 14-16 months of life and may help in deciding the optimal child age for universal familial hypercholesterolaemia screening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632410</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad547>10.1093/eurheartj/ehad547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632410</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sofie Taageby Nielsen</dc:creator>
<dc:creator>Rikke Mohr Lytsen</dc:creator>
<dc:creator>Nina Strandkjær</dc:creator>
<dc:creator>Ida Juul Rasmussen</dc:creator>
<dc:creator>Anne-Sophie Sillesen</dc:creator>
<dc:creator>R Ottilia B Vøgg</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Pia R Kamstrup</dc:creator>
<dc:creator>Kasper Iversen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Anne Tybjærg-Hansen</dc:creator>
<dc:creator>Ruth Frikke-Schmidt</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life</dc:title>
<dc:identifier>pmid:37632410</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad547</dc:identifier>
</item>
<item>
<title>High Costs of Cardiovascular Disease in the European Union</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad587. doi: 10.1093/eurheartj/ehad587. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632364</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad587>10.1093/eurheartj/ehad587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632364</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>William S Weintraub</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>High Costs of Cardiovascular Disease in the European Union</dc:title>
<dc:identifier>pmid:37632364</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad587</dc:identifier>
</item>
<item>
<title>Economic burden of cardiovascular diseases in the European Union: a population-based cost study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37632363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 26:ehad583. doi: 10.1093/eurheartj/ehad583. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Cardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan- European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU) countries in 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Aggregate country-specific resource use data on morbidity, mortality, and health, social and informal care were obtained from international sources, such as the Statistical Office of the European Communities, enhanced by data from the European Society of Cardiology Atlas programme and patient-level data from the Survey of Health, Ageing and Retirement in Europe. Country-specific unit costs were used, with cost estimates reported on a per capita basis, after adjustment for price differentials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equalling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD represented a cost of €630 per person, ranging from €381 in Cyprus to €903 in Germany. Coronary heart disease accounted for 27% (€77 billion) and cerebrovascular diseases for 27% (€76 billion) of CVD costs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37632363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37632363</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad583>10.1093/eurheartj/ehad583</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37632363</guid>
<pubDate>Sat, 26 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramon Luengo-Fernandez</dc:creator>
<dc:creator>Marjan Walli-Attaei</dc:creator>
<dc:creator>Alastair Gray</dc:creator>
<dc:creator>Aleksandra Torbica</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Radu Huculeci</dc:creator>
<dc:creator>Firoozeh Bairami</dc:creator>
<dc:creator>Victor Aboyans</dc:creator>
<dc:creator>Adam D Timmis</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Jose Leal</dc:creator>
<dc:date>2023-08-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Economic burden of cardiovascular diseases in the European Union: a population-based cost study</dc:title>
<dc:identifier>pmid:37632363</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad583</dc:identifier>
</item>
<item>
<title>Interatrial shunt devices for heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Aug 25. doi: 10.1038/s41569-023-00923-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37626203</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00923-w>10.1038/s41569-023-00923-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37626203</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Interatrial shunt devices for heart failure</dc:title>
<dc:identifier>pmid:37626203</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00923-w</dc:identifier>
</item>
<item>
<title>Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad572. doi: 10.1093/eurheartj/ehad572. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Atrial fibrillation (AF) is a chronic, progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 346 patients with drug-refractory paroxysmal AF were enrolled and randomized to contact-force guided radiofrequency ablation (CF-RF ablation, n = 115), 4-minute cryoballoon ablation (CRYO-4, n = 115), or 2-minute cryoballoon ablation (CRYO-2, n = 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence, and arrhythmia burden on implantable monitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P = 0.03). A documented recurrence of any atrial tachyarrhythmia ≥30 seconds occurred in 56.5%, 53.9%, and 62.9% of those randomised to CF-RF, CRYO-4, and CRYO-2, respectively (P = 0.65). Compared to the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0-100.0%) with CF-RF, 99.9% (IQR 93.3-100.0%) with CRYO-4, and 99.1% (IQR 87.0-100.0%) with CRYO-2 (P = 0.38).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37624879</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad572>10.1093/eurheartj/ehad572</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624879</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jason G Andrade</dc:creator>
<dc:creator>Marc W Deyell</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:creator>Jean Champagne</dc:creator>
<dc:creator>Peter Leong-Sit</dc:creator>
<dc:creator>Paul Novak</dc:creator>
<dc:creator>Lawrence Sterns</dc:creator>
<dc:creator>Jean-Francois Roux</dc:creator>
<dc:creator>John Sapp</dc:creator>
<dc:creator>Richard Bennett</dc:creator>
<dc:creator>Matthew Bennett</dc:creator>
<dc:creator>Nathaniel Hawkins</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Laurent Macle</dc:creator>
<dc:creator>CIRCA-DOSE Study Investigators</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</dc:title>
<dc:identifier>pmid:37624879</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad572</dc:identifier>
</item>
<item>
<title>TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827180640&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 25:ehad585. doi: 10.1093/eurheartj/ehad585. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to TR clinical stage as assessed using the TRI-SCORE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery and 645 transcatheter valve repair). The primary endpoint was survival at 2 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The TRI-SCORE was low (≤3) in 32%, intermediate (4-5) in 33% and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P &lt; 0.0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87% and 79%, respectively; P = 0.0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71% and 71%, respectively; P = 0.13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81% and 71%, respectively; P = 0.009). In the high TRI-SCORE category, survival was similar between groups even when restricted to patients with successful correction (61%, 68% and 58% respectively, P = 0.08).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827180640&v=2.17.9.post6+86293ac">37624856</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad585>10.1093/eurheartj/ehad585</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37624856</guid>
<pubDate>Fri, 25 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julien Dreyfus</dc:creator>
<dc:creator>Xavier Galloo</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Gregor Heitzinger</dc:creator>
<dc:creator>Giovanni Benfari</dc:creator>
<dc:creator>Karl-Patrick Kresoja</dc:creator>
<dc:creator>Fernando Juarez-Casso</dc:creator>
<dc:creator>Hazem Omran</dc:creator>
<dc:creator>Yohann Bohbot</dc:creator>
<dc:creator>Christos Iliadis</dc:creator>
<dc:creator>Giulio Russo</dc:creator>
<dc:creator>Yan Topilsky</dc:creator>
<dc:creator>Marcel Weber</dc:creator>
<dc:creator>Luis Nombela-Franco</dc:creator>
<dc:creator>Alessandra Sala</dc:creator>
<dc:creator>Andrea Eixerés-Esteve</dc:creator>
<dc:creator>Bernard Iung</dc:creator>
<dc:creator>Jean-François Obadia</dc:creator>
<dc:creator>Rodrigo Estevez Loureiro</dc:creator>
<dc:creator>Elisabeth Riant</dc:creator>
<dc:creator>Erwan Donal</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>Luigi Badano</dc:creator>
<dc:creator>Thierry Le Tourneau</dc:creator>
<dc:creator>Augustin Coisne</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Jose Luis Zamorano</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>John Webb</dc:creator>
<dc:creator>Denisa Muraru</dc:creator>
<dc:creator>Mohammed Nejjari</dc:creator>
<dc:creator>Vincent Chan</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:creator>Manuel Carnero-Alcazar</dc:creator>
<dc:creator>Georg Nickenig</dc:creator>
<dc:creator>Roman Pfister</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Volker Rudolph</dc:creator>
<dc:creator>Juan Crestanello</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Philipp Bartko</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Jeroen Bax</dc:creator>
<dc:creator>Maurice Enriquez-Sarano</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:creator>TRIGISTRY investigators</dc:creator>
<dc:date>2023-08-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</dc:title>
<dc:identifier>pmid:37624856</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad585</dc:identifier>
</item>





























</channel>
</rss>